- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about UCBJY
Recent news which mentions UCBJY
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
August 06, 2025
From Benzinga
From Benzinga
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
May 09, 2025
From Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
April 09, 2025
From Benzinga
From Benzinga
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
March 07, 2025
From Benzinga
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
November 20, 2024
From Benzinga
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
November 20, 2024
From Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
September 24, 2024
From Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
September 10, 2024
From Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
From Benzinga
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
August 26, 2024
From Benzinga
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
January 02, 2024
From Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
From Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
August 31, 2023
From Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
From Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
From Benzinga
From Benzinga
From MarketWatch
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
March 28, 2022
From Benzinga
From Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
From Benzinga
From Benzinga
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
September 02, 2021
From Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
August 25, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
August 23, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.